Pseudomonal Infections - Pipeline Insight, 2024

This “Pseudomonal Infections- Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pseudomonal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pseudomonal Infections Understanding

Pseudomonal Infections: Overview

Pseudomonas infections are diseases caused by a bacterium from the genus Pseudomonas. The bacteria are found widely in the environment, such as in soil, water, and plants. They usually do not cause infections in healthy people. If an infection does occur in a healthy person, it is generally mild. More severe infections occur in people who are already hospitalized with another illness or condition, or people who have a weak immune system. Pseudomonades are fairly common pathogens involved in infections acquired in a hospital setting. Infections in the skin tend to be less severe than infections that occur in the blood or lungs. Specific symptoms depend on where the infection occurs: A bacterial infection of the blood is called bacteremia. A blood infection is one of the most severe infections caused by pseudomonas. Symptoms may include: fever, chills, fatigue, muscle and joint pain. Bacteremia with pseudomonas can also cause very low blood pressure, known as hemodynamic shock, which can lead to failure of other organs including the heart, kidneys, and liver. When this bacterium infects the skin, it most often affects the hair follicles. This is called folliculitis. Symptoms may include: redness of the skin, abscess formation in the skin and draining wounds. Pseudomonas infections can be very aggressive, particularly infections in the lungs or skin. Pseudomonas infections are caused by a free-living bacterium from the genus Pseudomonas. They favor moist areas and are widely found in soil and water. Only a few of the many species cause disease. The most common species that causes infection is called Pseudomonas aeruginosa. Healthy people are usually at low risk of infection. People who already have a weakened immune system because of another illness or condition are at a higher risk of infection. This is especially true for people who are hospitalized for an extended period of time. Pseudomonas infections are treated with antibiotics. Unfortunately, many pseudomonas infections are becoming more difficult to treat. These bacteria have developed the ability to adapt and overcome antibiotics in their environment. This is called antibiotic resistance. The increase in antibiotic resistance has made treating infections much more challenging. Pseudomonas infections can often develop resistance to multiple types of antibiotics. It can even sometimes develop resistance during the course of treatment.

Pseudomonal Infections- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pseudomonal Infections pipeline landscape is provided which includes the disease overview and Pseudomonal Infections treatment guidelines. The assessment part of the report embraces, in depth Pseudomonal Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pseudomonal Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pseudomonal Infections R&D. The therapies under development are focused on novel approaches to treat/improve Pseudomonal Infections.

Pseudomonal Infections Emerging Drugs Chapters

This segment of the Pseudomonal Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pseudomonal Infections Emerging Drugs

AP-PA02: Armata Pharmaceuticals AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an initial emphasis on cystic fibrosis (CF) patients. AP-PA02 is comprised of a cocktail of complementary P. aeruginosa phages that offer improved host range, increased potency, and aid in preventing the development of resistance. The drug is in Phase I b/II clinical trial studies.

AB569: Arch Biopartners AB569 constitutes an innovative method and potential candidate to treat mucoid and non mucoid P. aeruginosa pulmonary infections, as well as other types of bacterial pulmonary infections, that are resistant to traditional antibiotics. AB569 has potential to be modified for use in other indications, including adaptation as a topical cream for bacterial skin infections. AB569 has orphan drug status from the US FDA for the treatment of Pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. AB569 also has orphan medicinal product designation from the European Medicines Agency for the treatment of cystic fibrosis. The drug is in Phase I clinical studies for the treatment of bacterial infections and pseudomonalinfections.

BX 004 : Biom XBX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections, a main contributor to morbidity and mortality in this disease. Phase 1b/2a clinical study in CF patients is composed of two parts. Results from Part 1 aimed to evaluate the safety, pharmacokinetics, and microbiologic/clinical activity are expected in Q2 of 2022. Results from Part 2 aimed to demonstrate safety and efficacy are expected by Q3 of2022.

ETX 0462 : Entasis Therapeutics ETX0462 is a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens including, P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia spp. Similar to ß-lactam antibiotics, ETX0462 inhibits penicillin-binding proteins which are essential for bacterial cell wall biosynthesis, however, unlike ß-lactam antibiotics, ETX0462 is unaffected by ß-lactamase mediated resistance. ETX0462 is supported by CARB. Currently the drug is in Pre-Clinical stage of development for the treatment of Pseudomonal infections.

Pseudomonal Infections: Therapeutic Assessment

This segment of the report provides insights about the different Pseudomonal Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pseudomonal Infections

There are approx. 15+ key companies which are developing the therapies for Pseudomonal Infections. The companies which have their Pseudomonal Infections drug candidates in the most advanced stage, i.e. phase I/II include, Armata Pharmaceuticals.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pseudomonal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pseudomonal Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pseudomonal Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pseudomonal Infections drugs.

Pseudomonal Infections Report Insights

• Pseudomonal Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pseudomonal Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pseudomonal Infections drugs?
• How many Pseudomonal Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pseudomonal Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pseudomonal Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pseudomonal Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BiomX
• Zambon
• Polyphor
• Aridis Pharmaceuticals
• Armata Pharmaceuticals
• Arch Biopartners
• ContraFect
• AGILeBiotics
• ANTABIO

Key Products

• BX004
• AP-PA-02
• ABP-569
• ETX-0462
• ZP 044
• CF-370
• Murepavadin
• ABX 02

This product will be delivered within 1-3 business days.